[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1982

The Treatment of Dermatomycoses with Orally Administered Griseofulvin

Author Affiliations

Miami, Fla.

From the Division of Dermatology, Department of Medicine, University of Miami School of Medicine, Miami, Fla., and the Veterans Administration Hospital, Coral Gables, Fla.

Arch Dermatol. 1982;118(10):827-834. doi:10.1001/archderm.1982.01650220131019
Abstract

The systemic treatment of superficial fungus infections in man at last seems a near reality. Although the polyene antibiotics derived from streptomyces were a significant advance in antifungal chemotherapy against the yeast-like fungi, they failed to influence the common dermatomycoses.1 Recent studies demonstrating the influence of serum factors in superficial fungous infections illustrated the importance of blood-borne substances in confining cutaneous invasion by dermatophytes.2,15 Gentles' recent report of the successful oral treatment of Trichophyton and Microsporum infections in guinea pigs with griseofulvin, a product of several penicillia, was a great step forward.7 Subsequently, Lauder and O'Sullivan found it effective by mouth in calves with Trichophyton verrucosum infections.11 Our paper is a preliminary report of observations on the effectiveness of oral griseofulvin therapy in man.

Griseofulvin is a colorless, neutral, thermostable antibiotic isolated from Penicillium griseofulvin by Oxford, Raistrick, and Simonet,13 in 1939. Interest in the

First Page Preview View Large
First page PDF preview
First page PDF preview
×